300+ investors in your industry, stage, and region Get
Any industry
Hospitality
Video Games
EdTech
Restaurants
Google
Construction
Photography
Cryptocurrency
Clean Energy
CleanTech
Big Data
Email
Artificial Intelligence
Social Impact
Energy
SaaS
Mobile
Consumer
Health Care
Enterprise Software
Local
Platforms
Travel
InsurTech
Oil and Gas
Retail
Film
Payments
Marketplace
Organic Food
Fitness
Machine Learning
Agriculture (AgTech)
Gaming
B2B
Social Network
Wellness
Education
Medical Device
Automotive
eSports
Sports
Legal
Biotechnology
Renewable Energy
Facebook
Blockchain
Software
Medical
Web3
Theatre
Recruiting
Crowdfunding
Infrastructure
Venture Capital
Beauty
Fashion
Social
Celebrity
LGBT
Climate
Cannabis
Wine and Spirits
Mobile Apps
Life Science
Food and Beverage
Publishing
Art
Music
Real Estate
Sporting Goods
FinTech
Finance
Digital Media
Manufacturing
Social Media
Financial Services
Franchise
Non Profit
Internet
Mobile Advertising
Android
Sustainability
Proptech
Hardware
Impact
Transportation
Biotech
Enterprise
Community
Media (Entertainment)
Any country
Afghanistan
Greece
United Kingdom
Thailand
United Arab Emirates
Andorra
Benin
Japan
South Korea
Singapore
Burkina Faso
LATAM
Brazil
Africa
Gibraltar
Egypt
Oceania
Taiwan
Zimbabwe
Tunisia
Sweden
Hong Kong
Nigeria
Togo
Croatia
Iran
Guinea
Kyrgyzstan
Haiti
Norway
Lesotho
Isle of Man
Liberia
Malawi
Nepal
Mexico
Madagascar
Russian Federation
Sudan
Pakistan
Tajikistan
Zambia
Romania
Poland
Oman
Puerto Rico
Guernsey
Cameroon
Colombia
China
Armenia
Costa Rica
Czech Republic
Marshall Islands
Kuwait
Luxembourg
Malta
Namibia
Mozambique
Mauritius
Nicaragua
Panama
Serbia
Uzbekistan
Australia
New Zealand
Morocco
Jamaica
Sri Lanka
Switzerland
Guatemala
Kazakhstan
Cayman Islands
Venezuela
Uganda
Myanmar
Turkey
Uruguay
Moldova
Seychelles
Paraguay
Botswana
South Africa
France
Denmark
Georgia
Ghana
Iraq
Portugal
Philippines
Sierra Leone
El Salvador
Senegal
India
Germany
Canada
Ireland
Saudi Arabia
Latvia
Kenya
Mali
Malaysia
Rwanda
Tanzania
United States
Indonesia
Middle East
Bermuda
Dominican Republic
Asia
Albania
Angola
Europe
Cyprus
Spain
Qatar
Argentina
Bangladesh
Barbados
Belgium
Austria
Ethiopia
Jordan
Azerbaijan
Ecuador
Bulgaria
Faroe Islands
Estonia
Bahrain
Bahamas
Jersey
Bolivia
Belize
Algeria
Belarus
Finland
Italy
Hungary
Israel
Grenada
Honduras
Iceland
Lithuania
Cambodia
Liechtenstein
Lebanon
Mongolia
Peru
Slovenia
San Marino
Ukraine
Chile
Vietnam
Angel Investors
VC Funds
All Investors
Access Full Database - Free Forever
Open database
Huatai Zijin Investment, VC Fund

Huatai Zijin Investment

VC Fund

Nanjing, China

Huatai Zijin Investment is an invetsment Firm.

Total investments:
70
Last investment:
Lead investor:
34%

Last updated:

Industries Huatai Zijin Investment invests in

Health CareBiotechnologyManufacturingMedicalPharmaceutical

Stages Huatai Zijin Investment invests in

Series BSeries ASeries CSeedSeries D

Countries Huatai Zijin Investment invests in

ChinaUnited States

Round sizes

Series A $1.5M–$59MSeries B $15M–$223MSeries C $255k–$283M

Contacts

NameEmailPhoneSocials

Sign up to unlock verified contacts

Unlock Contacts

Round size

Series A
$1.5M–$59M
Series B
$15M–$223M
Series C
$255k–$283M

Investment Focus

Industry

  • Health Care 19 (27%)
  • Biotechnology 15 (21%)
  • Manufacturing 14 (20%)
  • Medical 11 (16%)
  • Pharmaceutical 11 (16%)
See all 54 industries →

Stage

  • Series B 21 (30%)
  • Series A 13 (19%)
  • Series C 8 (11%)
  • Seed 7 (10%)
  • Series D 5 (7%)
See all 10 stages →

Country

  • China 59 (84%)
  • United States 2 (3%)

Team

NameTitleInvestmentsLinksEmail
Chen Miao partner
partner Total investments: 3 Find email
Wang Qi investment director
investment director Total investments: 1 Find email

Investments

CompanyDescriptionRoundLinks
Gaowei Medicine Gaowei Medicine
Gaowei Medicine is a drug discovery platform for developing new drugs for key intractable diseases such as cancer and neurological diseases. Seed / Oct 14, 2026
Synphatec is an innovative biopharmaceutical company headquartered in Shanghai, China, developing next-generation therapies for central nervous system diseases. $50M / Series A / Sep 28, 2026
Juxie Intelligent is an intelligent technology company that specializes in the development, manufacturing and production of harmonic reducers. $14.9M / Series B / Sep 28, 2026
QL Biopharma focuses on developing innovative drugs and premium me-too drugs targeting metabolic diseases. $44.7M / Series C / Sep 14, 2026
YMC Semiconductor
YUMEI Semiconductor is a semiconductor equipment company that specializes in semiconductor services. Its primary activities include research and development, production, and sales of specific equipment for semiconductor devices. $223.2M / Series B / Aug 27, 2026
Pioneer Semiconductor develops semiconductor manufacturing equipment for ALD, PECVD, and epitaxial processes. Its product portfolio includes thermal ALD, plasma-enhanced ALD, silicon and silicon carbide epitaxy, PECVD, and atomic layer etching equipment. The equipment is used in semiconductor chip manufacturing, advanced packaging, power devices,RF components, and other applications. Pioneer Semiconductor also provides equipment installation, commissioning, technical training, parts supply, and after-sales support. $223.2M / Series B / Aug 27, 2026
SiranBio is a biotechnology that develops innovative siRNA drugs. $59.5M / Series A / Aug 20, 2026
Weiguang Energy Technology focuses on the research, manufacturing, and commercial application of advanced power electronics equipment, specifically solid-state transformers and energy routing technologies. The company operates a core business model centered on supplying tailored hardware and digital software platforms to optimize energytransformation. Its primary value proposition is to enhance efficiency, system safety, and battery life management within computing infrastructure, electrical transportation grids, and large-scale energy storage installations. Series B / Aug 02, 2026
Genta Kyushu Bio is a cutting edge biotechnology company specializing in the development of precision neuro circuit therapies for central nervous system and ophthalmic diseases. The firm leverages its high throughput screening and drug development platforms to advance innovative treatments utilizing chemogenetics, optogenetics, and gene therapies. $14.8M / Series A / Jul 30, 2026
Kai Medtech focuses on the research, development, production and sales of neurointerventional implantable medical devices. $73.9M / Series D / Jul 28, 2026
See all 70 investments →

Co-Investors

Access 48,091 investors

822 industries, 177 countries. Updated daily. Emails and phones included.

Browse database — It's Free!

Find investors for your startup

Search 48,091 investors by industry and country. Emails and phones included.

Any industry
Hospitality
Video Games
EdTech
Restaurants
Google
Construction
Photography
Cryptocurrency
Clean Energy
CleanTech
Big Data
Email
Artificial Intelligence
Social Impact
Energy
SaaS
Mobile
Consumer
Health Care
Enterprise Software
Local
Platforms
Travel
InsurTech
Oil and Gas
Retail
Film
Payments
Marketplace
Organic Food
Fitness
Machine Learning
Agriculture (AgTech)
Gaming
B2B
Social Network
Wellness
Education
Medical Device
Automotive
eSports
Sports
Legal
Biotechnology
Renewable Energy
Facebook
Blockchain
Software
Medical
Web3
Theatre
Recruiting
Crowdfunding
Infrastructure
Venture Capital
Beauty
Fashion
Social
Celebrity
LGBT
Climate
Cannabis
Wine and Spirits
Mobile Apps
Life Science
Food and Beverage
Publishing
Art
Music
Real Estate
Sporting Goods
FinTech
Finance
Digital Media
Manufacturing
Social Media
Financial Services
Franchise
Non Profit
Internet
Mobile Advertising
Android
Sustainability
Proptech
Hardware
Impact
Transportation
Biotech
Enterprise
Community
Media (Entertainment)
Any country
Afghanistan
Greece
United Kingdom
Thailand
United Arab Emirates
Andorra
Benin
Japan
South Korea
Singapore
Burkina Faso
LATAM
Brazil
Africa
Gibraltar
Egypt
Oceania
Taiwan
Zimbabwe
Tunisia
Sweden
Hong Kong
Nigeria
Togo
Croatia
Iran
Guinea
Kyrgyzstan
Haiti
Norway
Lesotho
Isle of Man
Liberia
Malawi
Nepal
Mexico
Madagascar
Russian Federation
Sudan
Pakistan
Tajikistan
Zambia
Romania
Poland
Oman
Puerto Rico
Guernsey
Cameroon
Colombia
China
Armenia
Costa Rica
Czech Republic
Marshall Islands
Kuwait
Luxembourg
Malta
Namibia
Mozambique
Mauritius
Nicaragua
Panama
Serbia
Uzbekistan
Australia
New Zealand
Morocco
Jamaica
Sri Lanka
Switzerland
Guatemala
Kazakhstan
Cayman Islands
Venezuela
Uganda
Myanmar
Turkey
Uruguay
Moldova
Seychelles
Paraguay
Botswana
South Africa
France
Denmark
Georgia
Ghana
Iraq
Portugal
Philippines
Sierra Leone
El Salvador
Senegal
India
Germany
Canada
Ireland
Saudi Arabia
Latvia
Kenya
Mali
Malaysia
Rwanda
Tanzania
United States
Indonesia
Middle East
Bermuda
Dominican Republic
Asia
Albania
Angola
Europe
Cyprus
Spain
Qatar
Argentina
Bangladesh
Barbados
Belgium
Austria
Ethiopia
Jordan
Azerbaijan
Ecuador
Bulgaria
Faroe Islands
Estonia
Bahrain
Bahamas
Jersey
Bolivia
Belize
Algeria
Belarus
Finland
Italy
Hungary
Israel
Grenada
Honduras
Iceland
Lithuania
Cambodia
Liechtenstein
Lebanon
Mongolia
Peru
Slovenia
San Marino
Ukraine
Chile
Vietnam
Angel Investors
VC Funds
All Investors

Similar Investors

Recommended lists

FAQ

What does Huatai Zijin Investment invest in?

Huatai Zijin Investment invests primarily in Health Care, Biotechnology and Manufacturing startups, most often at Series B and Series A stage. Most of the 70 investments tracked by Shizune back companies in China. The Investment Focus section breaks down every industry, stage and country in the portfolio.

What round sizes does Huatai Zijin Investment invest in?

Huatai Zijin Investment typically joins rounds of $1.5M–$59M at Series A, $15M–$223M at Series B and $255k–$283M at Series C. These are whole funding-round sizes, not Huatai Zijin Investment's own check, which is rarely disclosed: the 10th–90th percentile of the confirmed public funding rounds Huatai Zijin Investment took part in.

How do I contact Huatai Zijin Investment?

Public channels for Huatai Zijin Investment include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

Who are the partners at Huatai Zijin Investment?

The team at Huatai Zijin Investment includes Chen Miao (partner) and Wang Qi (investment director). The Team section lists each member with their title, investment count and links.

Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

Contact your first 100 investors today

Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.

Find investors — It's Free!
Huatai Zijin Investment Huatai Zijin Investment Find emails